Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06432751
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2024-05-17
Brief Title:
Pre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Pre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SGLT2i-PO-AKI
Brief Summary:
Cardiac surgery with cardiopulmonary bypass exposes patients to the risk of post-operative acute kidney injury In the specific setting of cardiac surgery acute kidney injury is often of multifactorial origindue to particular haemodynamic mechanisms renal hypoxia or damage linked in the inflammatory reaction or haemolysis
In recent years inhibitors of the sodiumglucose co-transporter type 2 have demonstrated their relevance in reducing the morbidity and mortality associated with chronic or acute heart failure and chronic kidney disease These drugs were initially developed to optimise glycaemic control in diabetic patients They are currently recommended as part of the management of diabetic patients at high cardiovascular risk patients with systolic andor diastolic heart failure and patients with chronic kidney disease
Some pharmacodynamic properties of SGLT2i suggest that they could have a beneficial effect in preventing the onset of acute kidney injury but also that they could lead to potentially deleterious effects in renal haemodynamic in specific situations
The aim of the study was to estimate the impact of pre-operative exposure to SGLT2i on the occurrence of post-operative acute kidney injury in high-risk renal patients undergoing cardiac surgery
In recent years inhibitors of the sodiumglucose co-transporter type 2 have demonstrated their relevance in reducing the morbidity and mortality associated with chronic or acute heart failure and chronic kidney disease These drugs were initially developed to optimise glycaemic control in diabetic patients They are currently recommended as part of the management of diabetic patients at high cardiovascular risk patients with systolic andor diastolic heart failure and patients with chronic kidney disease
Some pharmacodynamic properties of SGLT2i suggest that they could have a beneficial effect in preventing the onset of acute kidney injury but also that they could lead to potentially deleterious effects in renal haemodynamic in specific situations
The aim of the study was to estimate the impact of pre-operative exposure to SGLT2i on the occurrence of post-operative acute kidney injury in high-risk renal patients undergoing cardiac surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None